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A B S T R A C T
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a genetic disorder with an incidence of ~1:20,000
that manifests in a wide range of renal and liver disease severity in human patients and can lead to perinatal
mortality. ARPKD is caused by mutations in PKHD1, which encodes the large membrane protein, Fibrocystin,
required for normal branching morphogenesis of the ureteric bud during embryonic renal development. The
variation in ARPKD phenotype suggests that in addition to PKHD1mutations, other genes may play a role, acting
as modifiers of disease severity. One such pathway involves non-canonical Wnt/Planar Cell Polarity (PCP)
signalling that has been associated with other cystic kidney diseases, but has not been investigated in ARPKD.
Analysis of the AtminGpg6 mouse showed kidney, liver and lung abnormalities, suggesting it as a novel mouse tool
for the study of ARPKD. Further, modulation of Atmin affected Pkhd1 mRNA levels, altered non-canonical Wnt/
PCP signalling and impacted cellular proliferation and adhesion, although Atmin does not bind directly to the C-
terminus of Fibrocystin. Differences in ATMIN and VANGL2 expression were observed between normal human
paediatric kidneys and age-matched ARPKD kidneys. Significant increases in ATMIN, WNT5A, VANGL2 and
SCRIBBLE were seen in human ARPKD versus normal kidneys; no substantial differences were seen in DAAM2 or
NPHP2. A striking increase in E-cadherin was also detected in ARPKD kidneys. This work indicates a novel role
for non-canonical Wnt/PCP signalling in ARPKD and suggests ATMIN as a modulator of PKHD1.
1. Introduction
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a rare
hereditary disorder, affecting 1:20,000 to 1:40,000 individuals, mostly
foetuses and infants [1] and is a common cause of perinatal death [2]. It
manifests as extreme bilateral enlargement of cystic kidneys in utero,
associated with hepatic ductal plate abnormalities and pulmonary hy-
poplasia [3,4]. In those patients who survive the perinatal period, the
majority will require renal replacement therapy (dialysis/transplanta-
tion) within the first decade [5]. Recently, however, ARPKD patients
have been diagnosed in their 30s with relatively mild renal
insufficiency [6]. Besides the typical renal manifestations associated
with ARPKD, a significant percentage of ARPKD patients manifest
extra-renal phenotypes, such as liver fibrosis and dilated bile ducts
(Caroli's syndrome) [7], suggesting a previously unrecognised, wide
spectrum of disease severity.
ARPKD is caused by mutations in PKHD1, the gene encoding
Fibrocystin. Fibrocystin is a membrane-associated receptor-like protein
of 447 kDa, composed of a large, modular extracellular N-terminal
domain, a single transmembrane domain and a short intracellular C-
terminal region [8]. Many different mutations in PKHD1 have been
reported throughout the whole gene and the combination of mutations
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determines the phenotype of ARPKD patients. Patients with two trun-
cating mutations have a lethal phenotype, whereas the presence of at
least one missense change can be compatible with life, indicating that
many missense mutations are hypomorphic alleles that generate par-
tially functional protein [9]. Modifier genes are also believed to play a
role in the range of disease severity observed in ARPKD [4,10–12].
Fibrocystin is required for normal branching morphogenesis of the
ureteric bud during embryonic renal development [8,13]. In ARPKD
kidneys, cystic dilation is restricted to the ureteric bud-derived col-
lecting tubules (CTs) and is associated with increased epithelial cell
proliferation and luminal fluid secretion [14], as well as abnormalities
in apoptosis [15,16], epithelial cell polarity [17] and cell-matrix in-
teractions [18]. Fibrocystin is also localised in primary cilia protruding
from the apical surface of CT cells [19,20], together with Polycystins
(PC)-1 and -2 [21], the protein products of the Autosomal Dominant
(AD)PKD-causative genes PKD1 and PKD-2 [3,4]. In the kidney, pri-
mary cilia are non-motile sensory organelles that act as signal trans-
ducers involved in cell signalling pathways [22]. Both canonical Wnt
and non-canonical Wnt/PCP pathways are relevant to ciliary signalling
and kidney development [23]. Loss of Fibrocystin function causes
shorter cilia in the bile ducts of a mouse model with no functional Fi-
brocystin [24].
Canonical Wnt signalling is initiated when Wnt ligands bind to
Frizzled (Fz) receptors in the presence of LRP5 or 6 [25]. This results in
Dishevelled (Dvl) activation and stabilisation of β-catenin, which then
translocates to the nucleus and initiates transcriptional activation of
Wnt target genes. The other key downstream Wnt signalling pathway in
the kidney is the non-canonical Wnt/PCP pathway. The binding of non-
canonical Wnt ligands here results in the recruitment of Fz and Dvl to
the membrane, culminating in cytoskeletal rearrangements that affect
cellular organisation, shape and migration. In the kidney, interaction of
Inversin with Dvl is hypothesised to trigger non-canonical Wnt/PCP
pathway activation [26]. Many core and effector PCP proteins have
been implicated in kidney development and disease and one of these is
Atmin, a transcription factor with diverse roles in DNA damage repair
and ciliogenesis [27–29]. Kidney development was demonstrated to be
greatly impaired in Atmin deficient mice, with homozygous mutant
kidneys displaying reduced numbers of differentiated ureteric buds and
renal vesicles [30]. Loss of Atmin resulted in changes in expression of
non-canonical Wnt components (Wnt9b, Wnt11, Vangl2, Daam2) that
affected oriented cell division and the cytoskeletal organisation in the
renal epithelial cells of the kidney.
The significant role of Wnt signalling is gaining recognition in cystic
renal disease. Disrupted Wnt signalling components, including Wnt9b,
Fat4, Vangl2 and Inversin are associated with polycystic kidney disease
[31–36] and frizzled-related-protein-4 is upregulated in human ADPKD
and in ADPKD mouse models [37]. Furthermore, DKK3, a β-catenin
antagonist, is a potential modifier of ADPKD [38] and Wnt ligands bind
to the PKD1-encoded PC-1 extracellular domain and activate the PC-1/
PC-2 channel [39]. While defective Wnt signalling has been implicated
in ADPKD and mis-oriented cell division was detected in Pck rats [40],
the role of non-canonical Wnt/PCP signalling has not been investigated
in detail in human ARPKD. Hence an examination of novel Wnt path-
ways implicated in ARPKD was conducted in mice, cell lines and human
kidneys, providing a unified approach into understanding paediatric
polycystic kidney disease mechanisms.
2. Materials and methods
2.1. Mice
The ENU-derived AtminGpg6 mice were identified in an ENU muta-
genesis screen at MRC Harwell, as previously described [27,41]. Gpg6
mice show a T to A transversion in exon 3 of Atmin, correlating with the
third Zinc Finger. This results in a cysteine to serine substitution in the
fourth canonical residue. Genotyping was carried out using
pyrosequencing assays to directly amplify the mutations; wildtype lit-
termates were used as controls (primers available on request). Work
was conducted under Home Office project licence number 30/3286.
2.2. Antibodies
Western blotting was carried out using 40 μg of whole tissue lysate
per lane with the E-cadherin antibody (1:1000, 3195, Cell signalling),
β-catenin antibody (1:1000, 9582, Cell signalling), non-phospho active
β-catenin antibody (1:1000, 8814S, Cell signalling), GAPDH (1:1000,
ab8245, Abcam) and β-actin antibody (1:5000, A5316, Sigma). For the
Atmin siRNA-mediated knockdown immunocytochemistry, E-cadherin
(1:500, 3195, Cell signalling) was used.
2.3. Cell culture and siRNA knockdowns
Mouse inner medullary collecting duct (mIMCD3) cells (gift from D.
Norris, MRC Harwell) were grown in DMEM/F12 (Gibco) media sup-
plemented with 2% fetal bovine serum (Life Technologies) and peni-
cillin-streptomycin (Life Technologies) in 1% collagen-coated 6-well
plates (VWR). mIMCD3 cells were transfected with Lipofectamine
RNAimax transfection reagent (Thermo Fisher), using siRNA to knock
down Atmin, Pkhd1 or Pkhd1 and Atmin, according to the manufac-
turer's instructions (Thermo Fisher); scrambled siRNA was used as a
control (Thermo Fisher). For each experiment, at least three biological
samples per group were used and for each sample, three technical re-
plicates were performed.
2.4. Quantitative RT-PCR analysis
To measure gene expression levels, RNA was extracted using the
RNeasy mini kit as per manufacturer's instructions (QIAGEN). 1 μg of
RNA was isolated per sample and cDNA was prepared for qRT–PCR
using the High Capacity cDNA Reverse transcription kit (ABI). qRT-PCR
was performed for: ATMIN, DAAM2, NPHP2, WNT5A, VANGL2, SCRI-
BBLE, β-CATENIN, Atmin, Pkhd1, Scribble, Wnt5a, Vangl2, Nphp2, Axin2.
All assays were provided by ABI and were run on the ABI ViiA 7 Real-
Time PCR system. Alterations in gene expression were expressed re-
lative to the mean intensity in control (normal human kidney or
scrambled control) over B2M and β-actin expression respectively,
which was given a standardized value of 1. Negative controls without
cDNA template were included. All qRT–PCR assays were performed in
triplicate. Primer details are available upon request.
2.5. Proliferation and apoptotic analysis
Proliferation and apoptotic indices were calculated by counting the
numbers of phospho-histone-H3 (1:500, 06–570, Millipore), or cleaved
caspase 3 (1:500, 9661, Cell signalling)-positive cells, respectively, in
10 comparable fields per mouse kidney or gene knockdown, as a per-
centage of DAPI-stained nuclei (n=4 biological samples per genotype
or group). Immunofluorescence analysis was carried out using a Leica
DM2500 optical microscope with the Leica applications suite software.
Adobe Photoshop CS7 software was used to compose and analyse the
images.
2.6. Cell adhesion analysis
Post siRNA knockdown, 50,000 mIMCD3 cells were grown as de-
scribed above, washed twice in PBS, fixed for 10min in 4% PFA and
then stained for 10min with 0.1% crystal violet solution. Stained cells
were washed off with running water until the run-off became clear, left
to dry overnight and then solubilised in 100% methanol. The solubi-
lised crystal violet was read in a 570 nm wavelength spectrophotometer
(Thermo Labsystems Multiskan MS plate reader). Results were obtained
by subtracting background absorbance, were deducted from control
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sample and multiplied by 100% for percentage adherence (n=4 bio-
logical samples per group).
2.7. Overexpression studies, immunoprecipitation and Western blot analysis
of transfected cells
mIMCD3 cells were transfected with ATMIN-MYC cDNA (gift from
D. Norris, MRC Harwell) using jetPRIME transfection reagent
Fig. 1. Cytoskeletal differences are detected in E13.5 AtminGpg6/+ embryos. AtminGpg6/+ kidneys (B) were smaller than wildtype (A), with a reduced number of
ureteric bud tips (I). In z-stack images of wildtype (C, E) and AtminGpg6/+ (D, F) kidneys, epithelial cells appeared disorganised and were difficult to distinguish from
the mesenchyme. AtminGpg6/+ lungs (H) were severely hypomorphic compared to age-matched wildtype lungs (G) and showed a reduction in the number of airways
(J). Decreased active β-catenin expression was observed in AtminGpg6/+ kidneys compared to wildtype (K, L, M). Images are representative of at least six animals per
group.
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Fig. 2. The AtminGpg6 phenotype mimics ARPKD. 4-month
old AtminGpg6/+ kidneys stained with haemotoxylin and
eosin showed tubule dilation (black box, B and I) and
disorganised (black arrows) ureteric-bud derived struc-
tures (B) that were not observed in age-matched wildtype
kidneys (A). Increased fat deposits were detected in
AtminGpg6/+ livers (D, black arrows, J), a phenotype which
was not seen in normal littermates (C; n=8 per geno-
type). The increased number of fat deposits was confirmed
by caveolin-1 staining of wildtype (white arrows, E) and
AtminGpg6/+ (white arrows, F) livers, with an average of 8
vs 18 caveolin-1 stained deposits per 100mm2 (K) being
identified. Increased water and food consumption was
observed in 4-month old AtminGpg6/+ mice (G, n= 12 per
group, *p < 0.05) without a change in body weight or
urine production or a significant difference in the al-
bumin/creatinine ratio between AtminGpg6/+ and normal
littermates (H).
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(Polyplus). After 48 h, RNA was extracted using the RNeasy mini kit as
per manufacturer's instructions (QIAGEN).
Human embryonic kidney HEK293T cells were transfected with
either ATMIN-MYC cDNA (gift from D. Norris, MRC Harwell), PKHD1-
GFP cDNA (Plasmid no. 45560, Addgene) or both, using jetPRIME
transfection reagent (Polyplus). After 48 h, cells were lysed using lysis
buffer (50mM Tris pH 8, 150mM NaCl, 1% NP-40 and EDTA-free
protease (Roche) and PhosSTOP phosphatase (Roche) inhibitors) and
centrifuged to remove insoluble debris. Immunoprecipitation from
cleared lysates was performed using rabbit-anti-MYC (C3956, Sigma-
Aldrich) and mouse-anti-GFP (11814460001, Roche) antibodies, re-
spectively overnight at 4 °C. Primary antibodies were captured using
Protein G sepharose (Sigma-Aldrich) for 2 h at 4 °C. Immunocomplexes
were then washed using lysis buffer and eluted in electrophoresis LDS
loading buffer (Invitrogen).
Cell lysates and immunoprecipitates were separated by electro-
phoresis using NuPAGE gel (Invitrogen) and transferred to ni-
trocellulose membranes using the iBlot transfer system (Invitrogen).
Membranes were blocked for 1 h in blocking solution (5% skimmed
milk in PBS, 0.1% Tween 20 (PBST)) and then incubated in primary
antibody (rabbit-anti-MYC (Sigma Aldrich) or rabbit-anti-GFP (in-
house)) diluted in blocking solution overnight at 4 °C. After extensive
washing in PBST, membranes were incubated for 1 h in the corre-
sponding secondary antibody (goat-anti-rabbit-HRP (A6154, Sigma
Aldrich) for MYC blot and EasyBlot anti-rabbit-HRP (GTX221666-01,
Genetex) for GFP blot) diluted in blocking solution and washed as
above. Western blots were visualised by ECL.
2.8. Human tissue
Newborn to 18 years of age ARPKD and age-matched normal human
kidney samples were procured in a sterile fashion either immediately
post-mortem or from the operating room, at time of nephrectomy prior
to transplant and anonymised at source by National Institute's of Health
(NIH) ethically-approved National Disease Research Interchange
(NDRI, Philadelphia, USA) with full Institutional Review Board (IRB)/
NIH approval in USA and in UK with UCL ethical approval (Number 05/
Q0508/6), processed and stored in the PKD Charity UK-sponsored
Bioresource Bank. No samples had been subjected to warm ischaemia
and all were routinely validated by a trained in-house pathologist.
2.9. Histology and immunostaining
Kidneys were fixed in 4% paraformaldehyde in PBS for 4 h, rinsed in
PBS, dehydrated, wax-embedded and sectioned at 5 μm.
Immunohistochemistry was performed on tissue sections using the
following antibodies: ATMIN (1:1000, AB3271, Millipore), VANGL2
(1:500, gift from C. Dean; [42]), Inversin (1:500, ab65187, Abcam), β-
catenin (1:500, 9582, Cell signalling), Fibrocystin (1:200, sc-99139,
Santa Cruz), Caveolin-1 (3267, Cell Signalling). Alexa Anti-Rabbit 488
(1:500, ab150077, Abcam) or Alexa anti-rabbit 594 (1:500, ab150080,
Abcam) was used as the secondary antibody.
2.10. Statistical methods
Data were analysed using unpaired two-tailed t-tests, unless other-
wise stated. Significance was accepted at P < 0.05; error bars in all
data represent standard error of the mean.
3. Results
3.1. The AtminGpg6/+ mouse line exhibits kidney abnormalities and mimics
ARPKD
Our previous work on embryonic AtminGpg6 mice demonstrated that
Atmin plays a role in kidney development by modulating Wnt signalling
and provided evidence of severe lung hypoplasia in embryonic day (E)
13.5 AtminGpg6/Gpg6 mice [27,30]. As the AtminGpg6/Gpg6 homozygous
mice display embryonic lethality and die around E14 [27], it was not
possible to investigate whether the observed kidney defects would lead
to renal cysts in post-natal mice. A detailed analysis of the AtminGpg6/+
mice, which survive to adulthood, was thus conducted. Histological
examination of E13.5 wildtype and AtminGpg6/+ littermate kidneys
stained with Periodic acid-Schiff (PAS) revealed a small reduction in
size in the AtminGpg6/+ kidneys (Fig. 1A, B), accompanied by a reduced
number of ureteric bud tips in the AtminGpg6/+ kidneys (40 vs 32,
Fig. 1I), indicative of branching morphogenesis defects. After staining
with pan-cytokeratin, E13.5 AtminGpg6/+ kidneys displayed shorter,
broader ureteric bud tips compared to age-matched wildtype kidneys
(Fig. 1D vs C), with epithelial cells appearing disorganised and ran-
domly orientated, making them difficult to distinguish from the sur-
rounding mesenchyme (Fig. 1E, F and insets). E13.5 AtminGpg6/+ mice
also manifested lung hypoplasia (Fig. 1H) and a considerable reduction
in the average number of airways (Fig. 4J), relative to the lungs of age-
matched wildtype mice (15 vs 8, Fig. 1G, J).
To investigate the underlying cause for the reduced number of
epithelial structures in E13.5 AtminGpg6/+ kidneys, potential alterations
in proliferation or apoptosis were investigated. No significant difference
was detected in the percentage of proliferating cells (Supplementary
Fig. S1A) or in the levels of apoptosis (Supplementary Fig. S1B) in
AtminGpg6/+ kidneys compared to age-matched wildtype. When in-
vestigating β-catenin protein expression in E13.5 AtminGpg6/+ and age-
matched wildtype kidneys, a mild but statistically significant 25% re-
duction in active β-catenin was observed in AtminGpg6/+ kidneys com-
pared to age-matched, wildtype litter mates (Fig. 1K, L, M, p < 0.05).
An investigation for kidney abnormalities was also conducted in 4-
month old AtminGpg6/+ mice compared to age-matched wildtype lit-
termates. Interestingly, disorganised kidneys (black arrows, Fig. 2B)
displaying dilated tubules (black box, Fig. 2B) were identified in At-
minGpg6/+ mice (average length to width ratio of dilated tu-
bules= 2.069, Fig. 2I), a phenotype that was not detected in age-
matched wildtype kidneys (average length:width ratio of kidney tu-
bules= 3.98, Fig. 2I). The AtminGpg6/+ mice manifested a statistically
significant increase in food and water consumption, without a notice-
able change in body weight or urine production (Fig. 2G), a change in
the albumin/creatinine ratios (Fig. 2H) or significant differences in
urine sodium, potassium, chloride, calcium, glucose, urea, uric acid,
creatinine and inorganic phosphorus levels (Supplementary Fig. S2)
compared to age-matched wildtype littermates. Furthermore, At-
minGpg6/+ livers displayed an increased number of fat deposits (26 fat
deposits/1mm2 liver area, black arrows, Fig. 2D, J), compared to
normal age-matched livers (7 fat deposits/1mm2 liver area, Fig. 2C, J,
p < 0.01). This was verified by caveolin-1 immunostaining that
echoed the increase in fat deposits in the AtminGpg6/+ liver compared to
age matched wildtype (18 fat deposits per 100mm2 versus 8 fat de-
posits per 100mm2, Fig. 2E, F, K). Thus it appears that the AtminGpg6
mouse line that shows combined defects in the kidney, liver and lung
could provide a novel tool for the study of the molecular mechanisms of
ARPKD.
3.2. Atmin modulates Pkhd1 levels in mouse inner medullary collecting duct
3 cells
Many mutations associated with human disease result in a mod-
ulation of gene expression as opposed to its complete eradication. It is
also informative to study transcriptional regulation by modifying levels
of mRNA expression, as a clear readout of the relationship between
genes. To investigate whether Atmin could affect Pkhd1 transcription,
siRNA knockdown experiments were conducted in mouse inner me-
dullary collecting duct 3 (mIMCD3) cells that express high mRNA levels
of Atmin and Pkhd1 (Supplementary Fig. S3), with the aim of reducing
but not completely abolishing gene expression, in order to be able to
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Fig. 3. Atmin modulates Pkhd1 mRNA expression in mIMCD3 cells. (A) A 0.35-fold decrease in Pkhd1 mRNA was seen in the Atmin siRNA knockdown, accompanied
by a 0.3-fold decrease in Vangl2 and a 0.33-fold decrease in Wnt5a mRNA levels (n=3, *p < 0.05) (B-E) Increased E-cadherin expression is observed in the Atmin
knockdown cells compared to scrambled control. Substantially expanded E-cadherin distribution (white arrows) was only seen in the Atmin knockdown cells (n=4
per experimental condition). (F) In the Atmin-myc transfected mIMCD3 cells, a 103-fold increase in Atmin and a 6-fold increase in Pkhd1 was detected (n=3,
*p < 0.05). (G) A 0.4-fold reduction in Atmin mRNA expression was observed in the Pkhd1 siRNA knockdown (red). The double Atmin-Pkhd1 siRNA knockdown
(green) resulted in a 0.4-fold increase in Pkhd1 mRNA expression, restoring Pkhd1 expression to levels close to scrambled (blue, n=3, *p < 0.05). (H) A 0.6-fold
increase in Scribble mRNA expression was seen in the Pkhd1 siRNA knockdown, whereas Scribble mRNA expression was restored to the levels detected in the
scrambled control upon simultaneous Atmin siRNA knockdown. (n=3,* p < 0.01). A 0.5-fold decrease in Wnt5a and Vangl2 mRNA expression was revealed in the
Pkhd1 siRNA knockdown and this effect was not rescued by Atmin siRNA knockdown. No significant difference was detected in Nphp2 and Axin2 mRNA expression in
any siRNA knockdown (n=3, p > 0.05). For each experiment in A, F, G, H, at least three biological samples were used per group and for each sample, three
technical replicates were performed. (I) Immunoprecipitation of ATMIN-MYC from lysates of HEK293T cells co-transfected with Atmin-Myc cDNA and C-terminal
Pkhd1-Gfp cDNA and Western blot analysis did not reveal an interaction between the overexpressed proteins.
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examine Atmin-Pkhd1 interactions. Single Atmin knockdowns were
performed in mIMCD3 cells, resulting in an 80% reduction in Atmin
mRNA expression (Fig. 3A). Consistent with previously published work
[30], Atmin knockdowns reduced Vangl2 mRNA expression by 30%
(Fig. 3A, red). In addition, a 33% decrease was observed in Wnt5a
mRNA expression, while the Scribble, Nphp2 (the gene that encodes
Inversin) and Axin2 mRNA levels remained unchanged. Furthermore, a
notable increase in E-cadherin expression was seen in the Atmin
knockdown cells (Fig. 3D, E) compared to scrambled controls (Fig. 3B,
C), as well as markedly expanded areas of E-cadherin distribution being
frequently observed only in the Atmin knockdowns (white arrows,
Fig. 3D).
Interestingly, in the single Atmin knockdowns a statistically sig-
nificant 35% decrease in Pkhd1 mRNA levels was also observed
(Fig. 3A). To further investigate the Atmin-Pkhd1 relationship, full
length myc-tagged Atmin was overexpressed in mIMCD3 cells. This
caused a 6-fold increase in Pkhd1 mRNA levels (Fig. 3F, orange),
without affecting Pkd1, Pkd2 or Nphp2 mRNA expression.
Moreover, Pkhd1 alone and Pkhd1 together with Atmin were
knocked down in mIMCD3 cells. Pkhd1 knockdown resulted in a 50%
decrease in Pkhd1 expression (Fig. 3G, red); interestingly, this was ac-
companied by a 36% reduction in Atmin expression. Atmin-Pkhd1
double knockdown resulted in a 66% decrease in Atmin levels. Sur-
prisingly, this decrease in Atmin expression restored Pkhd1 expression
to levels similar to those of the scrambled control samples (81% Pkhd1
expression in Atmin-Pkhd1 double knockdown compared to 100%
Pkhd1 expression in scrambled).
Further investigation into the mRNA expression levels of non-ca-
nonical Wnt/PCP genes demonstrated a 45% decrease in Wnt5a and a
65% reduction in Vangl2 mRNA expression in the Pkhd1 knockdown
cells (Fig. 3H, red). The additional reduction in Atmin expression in the
Atmin-Pkhd1 knockdown (Fig. 3H, green) did not significantly change
Wnt5a and Vangl2 expression. Moreover, the Pkhd1 knockdown caused
a 60% increase in Scribble levels, which was restored to normal ex-
pression levels in the Atmin-Pkhd1 double knockdown (Fig. 3H), de-
monstrating that loss of Atmin can modulate Scribble mRNA expression.
No change was observed in Nphp2 and Axin2, either in the Pkhd1 or the
Atmin-Pkhd1 double knockdowns.
The C-terminus of Fibrocystin has been demonstrated to contain
important protein binding motifs, such as a nuclear localisation signal
[43], a ciliary target sequence [44] and a PC-2 binding domain [45],
making it a likely candidate for protein-protein interactions. To shed
further light on the interaction between Atmin and Pkhd1, full length
myc-tagged Atmin and the last 193 amino acids of the C-terminus of
GFP-tagged Fibrocystin were over-expressed in HEK293T cells. Both
forward (Fig. 3I) and reverse (Supplementary Fig. S4) co-IPs did not
show a direct interaction between Atmin and the C-terminus of Fi-
brocystin.
3.3. Atmin has no effect on apoptosis but reduces cellular proliferation and
adhesion in cells lacking Pkhd1
Since ARPKD has been associated with alterations in cellular pro-
liferation and apoptosis [4,15], both were investigated in the Pkhd1 and
Atmin-Pkhd1 knockdowns, where the transcripts had been reduced to
~50%. No changes in apoptotic indices were found between scrambled,
Pkhd1 and Atmin-Pkhd1 knockdowns. The numbers of apoptotic cells,
detected with cleaved caspase 3 antibody, were similar in scrambled
(0.25%, Fig. 4A, C, J), Pkhd1 (0.19%, Fig. 4D, F, J) and Atmin-Pkhd1
(0.12%, Fig. 4G, I, J, p > 0.1) siRNA knockdowns. Furthermore, no
significant difference in the number of proliferating cells stained with
phospho-histone H3 (PH3) was observed between the scrambled con-
trol (Fig. 5A, C) and Pkhd1 knockdowns (Fig. 5D, F) and the average
proliferative indices were similar (1.1% for scrambled, 0.99% for
Pkhd1, Fig. 5J). Importantly, a statistically significant decrease in the
number of proliferating cells was seen in Atmin-Pkhd1 double
knockdown compared to the Pkhd1 single knockdown (Fig. 5G, I), with
an average proliferation index of 0.73% (Fig. 5J, p < 0.01). In addi-
tion, increased cell adhesion was observed in the Pkhd1 knockdowns
compared to scrambled controls (111% vs 100%, Fig. 5K). Significantly,
in the Atmin-Pkhd1 double knockdown, cell adhesion levels were re-
stored to control (98%, Fig. 5 K).Thus, a reduction in Atmin expression
in the context of Pkhd1 knockdown can affect cellular proliferation and
adhesion, signifying that changes in ATMIN expression may impact on
cellular changes in ARPKD cystic epithelia.
3.4. A substantial increase in non-canonical Wnt/PCP signalling is detected
in ARPKD
Altered cytoskeletal rearrangements may be caused by defective
non-canonical Wnt/PCP signalling and abnormal Wnt signalling has
been implicated in ADPKD [39]. Our published work showed that
Atmin modulates non-canonical Wnt/PCP signalling [27] and since
Atmin affected Pkhd1 mRNA levels, the expression patterns of core and
effector PCP proteins were examined in our previously characterised
[18] normal (strong Fibrocystin expression) and ARPKD (no Fibrocystin
expression, very large cysts) kidney tissues (Supplementary Fig. S5). In
normal human paediatric kidneys, ATMIN, VANGL2, Inversin and β-
catenin were expressed in ureteric bud epithelia (Fig. 6, white arrows).
Apparently higher levels of ATMIN and VANGL2 were observed in
ARPKD paediatric kidneys compared to age-matched normal kidneys,
including strong expression in cyst-lining epithelia (Fig. 6, red arrows).
Inversin and β-catenin were also highly expressed in ARPKD cyst-lining
epithelia (Fig. 6, red arrows), although overall levels of renal expression
appeared to be similar to those in normal kidneys. To investigate po-
tential changes in gene expression of Wnt signalling components, a
thorough analysis of mRNA expression levels of various canonical and
non-canonical Wnt signalling genes was conducted.
Across a number of ARPKD kidneys taken from patients who had
reached end stage renal disease aged 0–18 years, a significant 2-fold
increase in ATMIN mRNA expression was consistently observed com-
pared to normal paediatric kidneys (Fig. 7A, n=11, p < 0.01). No
difference in DAAM2 or NPHP2 expression was detected between
ARPKD and normal paediatric kidneys. In addition, in a severe ARPKD
sub-group where patients reached end stage renal disease at an age of
5 years or younger, there was a 2.7-fold increase in WNT5A mRNA
expression (Fig. 7B, n=6, p < 0.05). In the same ARPKD kidneys,
there was a 9-fold increase in VANGL2 and an 11-fold increase in
SCRIBBLE mRNA expression, compared to normal paediatric kidneys
(Fig. 7B, n=6, p < 0.01). Importantly, no change in β-catenin mRNA
expression was seen between normal and ARPKD kidneys, demon-
strating that ARPKD is associated with increased mRNA levels of non-
canonical Wnt/PCP components.
Consistent with published work that showed that ARPKD cells ex-
hibited increased adhesive properties and decreased polarised migra-
tion [18], a 2.74-fold increase in E-cadherin expression was observed in
paediatric ARPKD kidneys compared to age-matched normal kidneys
(Fig. 8A, B), signifying increased calcium-dependent cell-cell adhesion.
Given that E-cadherin has been shown to interact with β-catenin [46],
the expression of total β-catenin protein was assessed in normal and
ARPKD kidneys. A striking 87% decrease in normalised total β-catenin
levels was seen in ARPKD compared to age-matched normal kidneys
(Fig. 8C, D), indicating that non-canonical Wnt/PCP signalling changes
affect β-catenin protein but not mRNA levels in ARPKD.
4. Discussion
4.1. Non-canonical Wnt/PCP signalling in ARPKD
Non-canonical Wnt/PCP signalling is a complex pathway that has
been studied in various systems and disease processes; downstream
effects of this pathway involve cytoskeletal rearrangements and
T. Richards et al. BBA - Molecular Basis of Disease 1865 (2019) 378–390
384
transcriptional activation [25]. Although the initial activation of the
pathway (Wnt ligand binding to Fz receptor, Dvl attachment to the
membrane) is similar to canonical Wnt signalling, the involvement of
core PCP proteins such as the Vangls, results in variable outcomes that
impact on cellular signalling processes. Our work has shown a role for
non-canonical Wnt/PCP signalling in the autosomal recessive form of
PKD for the first time. Mis-localisation and increased expression of core
(VANGL2) and effector (ATMIN) PCP proteins were observed in ARPKD
kidneys. Furthermore, increased expression of non-canonical Wnt genes
(WNT5A, VANGL2, ATMIN, SCRIBBLE) was identified. The dramatic
increase in SCRIBBLE associated with loss of Fibrocystin both in ARPKD
kidneys and in Pkhd1 siRNA knockdown cells demonstrates a potential
involvement of Fibrocystin in Scribble regulation. This is com-
plemented by a ~3-fold increase in E-cadherin that is most likely re-
lated to the known interaction of Scribble with E-cadherin [47] and the
significant cytoskeletal re-organisation previously observed in ARPKD
cystic epithelial cells [18]. It also opens up the possibility that there is a
direct association between increased non-canonical Wnt/PCP signalling
and end-stage renal disease observed in ARPKD patients.
In the kidney, Inversin has been considered to act as a switch
Fig. 4. Apoptosis is unaffected by the Pkhd1 and Atmin-Pkhd1 siRNA knockdown in mIMCD3 cells. Quantitation of the percentage of apoptotic mIMCD3 cells stained
with anti-cleaved caspase 3 (A, D, G) and DAPI (B, E, H) revealed no significant differences in apoptosis (J) between scrambled control (C), Pkhd1 siRNA knockdown
(F) and Atmin-Pkhd1 siRNA knockdown (I, n=3, p > 0.05).
T. Richards et al. BBA - Molecular Basis of Disease 1865 (2019) 378–390
385
between the canonical and non-canonical Wnt pathways [26]. Although
a significant reduction in β-catenin protein (but not mRNA) expression
was noted in ARPKD kidneys, the expression of NPHP2mRNA remained
unchanged both in ARPKD kidneys and in siRNA knockdown experi-
ments in mIMCD3 cells. This implies that NPHP2 transcription is un-
likely to have significant involvement in ARPKD and that the observed
reduction in total β-catenin levels in ARPKD is a consequence of in-
creased non-canonical Wnt/PCP signalling, as dys-regulation of the
non-canonical Wnt/PCP pathway can impact on canonical Wnt signal-
ling.
Thus loss of Fibrocystin results in mis-regulated non-canonical Wnt/
PCP signalling, both in ARPKD kidneys and in the mIMCD3 mouse
collecting duct cell line. The observed discrepancies in the Wnt5a and
Vangl2 mRNA levels between knockdown mouse collecting duct cells
and human ARPKD kidneys might be due to either increased ATMIN
levels in ARPKD kidneys, modulation of which significantly affects non-
canonical Wnt/PCP signalling or differences in the transcriptional
regulatory mechanisms of Fibrocystin between mouse and human. This
is not surprising, given the different observed phenotypes of the Pkhd1
knockout mice compared to ARPKD patients.
4.2. The Atmin-Fibrocystin relationship
The most significant relationship that our work has dissected is the
one between ATMIN and Fibrocystin. Cytoskeletal, PCP-related defects
were observed in embryonic AtminGpg6/+ mice and kidney and liver
abnormalities were detected in adult AtminGpg6/+ mice. Modulation of
Atmin levels in mIMCD3 cells affected Pkhd1 mRNA expression and in
Fig. 5. Loss of Atmin impacts cellular proliferation and adhesion in the Atmin-Pkhd1 siRNA knockdown in mIMCD3 cells. Analysis of the percentage of proliferating
mIMCD3 cells stained with anti-phospho histone H3 (A, D, G) and DAPI (B, E, H) revealed no significant difference in proliferation (J) between scrambled control (C)
and Pkhd1 siRNA knockdown (F, n= 3, p > 0.05). A statistically significant decrease in proliferation was observed in the Atmin-Pkhd1 siRNA knockdown (I, J,
n= 3, *p < 0.05). (K) Increased cellular adhesion was detected in Pkhd1 siRNA knockdown but it was restored to scrambled control levels in the Atmin-Pkhd1 siRNA
knockdown (n=3, *p < 0.05).
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the double knockdowns, a simultaneous reduction in Atmin and Pkhd1
levels impacted cellular proliferation and adhesion. Interestingly, no
direct interaction between Atmin and the C-terminus of Fibrocystin was
observed by co-immunoprecipitation. Although the C-terminus of
Fibrocystin is believed to contain its nuclear localisation signal and
protein interaction domains, recent work has demonstrated that loss of
the C-terminus does not significantly affect Fibrocystin function [48],
raising questions as to its exact role. This could mean that Atmin may
interact with Fibrocystin through other domains of the Fibrocystin
protein or that there is genetic/intermediary protein interaction be-
tween Atmin and Fibrocystin that influences its transcriptional/trans-
lational regulation. In fact, STRING analysis has predicted that both
ATMIN and Fibrocystin interact with serine-threonine kinases that
might prove important for their function (data not shown). It is also
possible that there is a role for epigenetics in the Atmin-Fibrocystin
relationship and our future work will investigate for Atmin variants in
paediatric and adult ARPKD, in order to be able to shed more light on
the mechanisms of the Atmin-Fibrocystin interaction.
Although no change in proliferation indices was found when com-
paring all epithelial cells in wildtype and AtminGpg6/Gpg6 kidneys [30],
statistically significant differences were seen in the proliferative indices
of Atmin-Pkhd1 double knockdowns compared to Pkhd1 knockdowns
and scrambled controls in mIMCD3 cells (Fig.5). It is hence possible
that Atmin, at least in vitro, specifically affects the proliferation of cells
of collecting duct origin, such as mIMCD3 cells, which were the focus of
our current study. Nevertheless, loss of Fibrocystin is associated with
increased ATMIN expression in ARPKD kidneys and consistent with our
published work [30], loss of Atmin and Pkhd1 does not lead to changes
in apoptosis.
Recent work by Clark et al., 2018 has shown that ATMIN contains a
flexible, disordered region that allows it to control target gene expres-
sion [49]. In the case of ATMIN's known downstream target, LC8
[27,50], ATMIN binding on LC8 increases LC8 transcription to produce
more LC8. Once there is enough LC8, LC8 binds on ATMIN's disordered
region and switches off LC8 transcription. As more LC8 binds on
ATMIN, the rate of LC8 transcription decreases, this fine tuning being
Fig. 6. Immunohistochemistry of Wnt signalling proteins reveals differential localisation patterns between paediatric normal and ARPKD kidneys. ATMIN (A),
VANGL2 (C), Inversin (E) and β-catenin (G) were expressed in ureteric bud-derived collecting tubules in normal human paediatric kidneys (white arrows). In age-
matched ARPKD kidneys, strong ATMIN (B) and VANGL2 (D) expression was detected in cyst-lining epithelia (orange arrows). Moderate Inversin (F) and β-catenin
(H) expression was also observed in ARPKD cyst-lining epithelia (red arrows; n=4 per group).
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achieved by the number of ATMIN binding sites that are occupied by
LC8. In addition, LC8 binding to the C-terminal of ATMIN alters its
subcellular localisation [51], demonstrating that ATMIN's downstream
targets can modify its function. This complex transcriptional regulatory
role of ATMIN could apply to its other downstream targets, such as
Fibrocystin. It should be noted that our data shows different outcomes
in Atmin levels when there is Fibrocystin expression (knockdown ex-
periments in IMCD3 cells, Fig. 3) compared to when there is no Fi-
brocystin expression (ARPKD tissues, Supplementary Fig. S5), implying
that the levels of Fibrocystin might modulate ATMIN's transcription and
levels of expression. Our future work will concentrate on dissecting how
the levels of Fibrocystin may impact ATMIN's regulatory role in ARPKD.
Our work has also demonstrated that the AtminGpg6 mouse pheno-
type bears a similarity to paediatric ARPKD in humans, displaying
kidney, liver and lung defects. As there is currently no single mouse
model that displays the complete multi-organ spectrum of the ARPKD
phenotype, our mouse line might provide a useful tool for the parallel
study of all the tissues that are affected in severe, paediatric ARPKD,
although there is still a need for additional mouse lines that model
Caroli's disease more accurately. In conclusion, this work opens up the
possibility that Atmin modulates Pkhd1 and provides insights into novel
signalling pathways that could impact ARPKD progression, raising ex-
citing possibilities for future interventions and therapies.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbadis.2018.11.003.
Fig. 7. Increased non-canonical Wnt mRNA expression is detected in ARPKD tissues. (A) A statistically significant 2-fold increase in ATMIN mRNA expression was
observed in ARPKD kidneys (red, *p < 0.01) compared to normalised, age-matched controls (blue). No significant difference in DAAM2 and NPHP2 expression was
detected between ARPKD and normal kidneys (n= 11 per group, p > 0.05). (B) A 3-fold increase inWNT5AmRNA expression was observed in ARPKD kidneys (red,
*p < 0.01) compared to age-matched normal kidneys (blue). A 9-fold increase in VANGL2 and an 11-fold increase in SCRIBBLE expression was seen between ARPKD
(red, *p < 0.01) and normal (blue) kidneys. No significant difference in β-catenin expression was detected between ARPKD (red) and normal (blue) kidneys
(p > 0.05). n=6 per group.
Fig. 8. Altered E-cadherin and β-catenin expression in ARPKD kidneys compared to age-matched normal kidneys. Western blotting revealed a 2.74-fold increase (A,
B) in E-cadherin (E) and a 0.87-fold decrease in β-catenin (C, D) protein levels in ARPKD compared to age-matched normal kidneys (n=3, *p < 0.01). β-actin was
used as a loading control.
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